A Phase 3 interventional study of Avacincaptad Pegol and Sham in Geographic Atrophy and Macular Degeneration, sponsored by IVERIC bio, Inc.. Completed at 205 sites in 20 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.
Sponsored by IVERIC bio, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 13th largest by enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2020, is one of 15 in phase 3, and was the 67th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 448 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
This study is registered under IVERIC bio, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
IVERIC bio, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Astellas Pharma Inc has 8 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
Participants were randomized in a 1:1 ratio to the following monthly treatment groups:
At Month 12, the participants in the avacincaptad pegol 2mg treatment group were re-randomized to receive the study drug either on a monthly basis or on an every other month basis
The participants initially randomized to sham treatment continued with monthly sham administration through Month 23
All participants had a final follow up visit at Month 24
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received avacincaptad pegol (ACP) 2 milligram (mg)/eye via intravitreal (IVT) injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT injections monthly from month12 through month 23 (Year 2).
Drug: Avacincaptad Pegol
Participants received sham injections; through Month 11 (Year 1). At month 12, participants continued to receive monthly sham administration from month 12 through month 23 (Year 2).
Drug: Sham
Participants who received ACP 2mg monthly through Month 11 (Year 1) were re-randomized at month 12, to receive ACP 2 mg/eye via IVT injections every other month at months 13, 15, 17, 19, 21, and 23 and sham injections at months 12, 14, 16,18, 20, and 22.
Drug: Avacincaptad Pegol
Avacincaptad Pegol Intravitreal Injection
Also known as: Zimura (previous name), IZERVAY
Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12
GA was associated with age-related macular degeneration (AMD) and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least squares mean used to determine mean rate of change in GA growth (slope) was measured by FAF. LS mean \& SE were based on square-root transformation.
Time frame: Baseline to month 12
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24
GA was associated with AMD and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least square mean rate of GA growth (slope) was measured by FAF. LS mean \& SE were based on untransformed data.
Time frame: Baseline to month 24
Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months
BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS Visual Acuity Score (VAS) is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
Time frame: Baseline and month 24
Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months
BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. LL BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart.
Time frame: Baseline and month 24
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months
The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.
Time frame: Baseline, months 6, 12, and 18
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months
The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.
Time frame: Baseline and month 24
Number of Participants With Categorical One-level Loss in VFQ-25 Subscale
The National Eye Institute VFQ-25 measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively.Categorical one-level loss in each item was defined as decline of one or more levels at Month 24 on the original scale from Baseline (equivalently 20 points for general vision and 25 points for other vision items in a 0 to 100 scale).
Time frame: Baseline up to month 24
Time to Persistent Vision Loss
Vision loss event was defined as a loss of ≥ 15 letters (equivalent to a loss of 3 lines on the ETDRS chart) in BCVA from Baseline measured at any two or more consecutive visits up to Month 24. These parameters were chosen as a 3-line BCVA loss (equivalent to doubling of visual angle) is widely recognized as a significant deterioration in vision and a minimum of two consecutive visits was representative of persistent disease progression. BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS was defined as the number of letters read on the ETDRS chart. Min and max possible scores are 0-100. A higher score represents better visual functioning. Kaplan-Meier method was used for analysis. Participants with an event were reported and not the median time to event.
Time frame: Baseline up to month 24
Participants ≥ 50 years of age diagnosed with geographic atrophy (GA) that was at least partly within 1.5 mm radius from the foveal center were enrolled in the study.
| Milestone | Avacincaptad Pegol | Avacincaptad Pegol and Sham | Sham |
|---|---|---|---|
| Started | 225 | 0 | 223 |
| Treated | 225 | 0 | 222 |
| Completed | 200 | 0 | 205 |
| Not completed | 25 | 0 | 18 |
| Withdrew: Adverse event | 3 | 0 | 2 |
| Withdrew: Death | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 17 | 0 | 13 |
| Withdrew: Patient non-compliance | 1 | 0 | 0 |
| Withdrew: Not treated | 0 | 0 | 1 |
| Milestone | Avacincaptad Pegol | Avacincaptad Pegol and Sham | Sham |
|---|---|---|---|
| Started | 96 | 93 | 203 |
| Completed | 89 | 83 | 184 |
| Not completed | 7 | 10 | 19 |
| Withdrew: Death | 1 | 4 | 6 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 3 | 7 |
| Withdrew: Adverse event | 2 | 1 | 6 |
GA was associated with age-related macular degeneration (AMD) and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least squares mean used to determine mean rate of change in GA growth (slope) was measured by FAF. LS mean \& SE were based on square-root transformation.
| millimeters (mm)/year | Avacincaptad Pegol | Sham |
|---|---|---|
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 | 0.336 ± 0.032 | 0.392 ± 0.033 |
GA was associated with AMD and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least square mean rate of GA growth (slope) was measured by FAF. LS mean \& SE were based on untransformed data.
| mm^2/year | Avacincaptad Pegol | Avacincaptad Pegol and Sham | Sham |
|---|---|---|---|
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24 | 2.23 ± 0.124 | 2.10 ± 0.126 | 2.59 ± 0.085 |
BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS Visual Acuity Score (VAS) is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
| score on a scale | Avacincaptad Pegol | Sham |
|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months | -7.31 ± 1.07 | -6.48 ± 1.05 |
BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. LL BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart.
| score on a scale | Avacincaptad Pegol | Sham |
|---|---|---|
| Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months | -10.58 ± 1.20 | -9.1 ± 1.18 |
The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.
| score on a scale | Avacincaptad Pegol | Sham |
|---|---|---|
| Change at 6 months | -1.2 ± 10.56 | -1.6 ± 9.98 |
| Change at 12 months | -3.4 ± 11.05 | -3.6 ± 11.01 |
| Change at 18 months | -5.4 ± 12.80 | -4.7 ± 11.53 |
The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.
| score on a scale | Avacincaptad Pegol | Sham |
|---|---|---|
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months | -7.735 ± 0.950 | -7.023 ± 0.931 |
The National Eye Institute VFQ-25 measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively.Categorical one-level loss in each item was defined as decline of one or more levels at Month 24 on the original scale from Baseline (equivalently 20 points for general vision and 25 points for other vision items in a 0 to 100 scale).
| participants | Avacincaptad Pegol | Sham |
|---|---|---|
| Color Vision | 45 | 35 |
| Distance Vision | 56 | 43 |
| Near Vision | 61 | 49 |
| Peripheral Vision | 58 | 65 |
| General Vision | 58 | 58 |
| Dependency | 55 | 55 |
| Driving | 27 | 26 |
| General Health | 45 | 67 |
| Mental Health | 35 | 42 |
| Ocular Pain | 27 | 20 |
| Role Difficulties | 60 | 59 |
| Social Function | 52 | 52 |
Vision loss event was defined as a loss of ≥ 15 letters (equivalent to a loss of 3 lines on the ETDRS chart) in BCVA from Baseline measured at any two or more consecutive visits up to Month 24. These parameters were chosen as a 3-line BCVA loss (equivalent to doubling of visual angle) is widely recognized as a significant deterioration in vision and a minimum of two consecutive visits was representative of persistent disease progression. BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS was defined as the number of letters read on the ETDRS chart. Min and max possible scores are 0-100. A higher score represents better visual functioning. Kaplan-Meier method was used for analysis. Participants with an event were reported and not the median time to event.
| months | Avacincaptad Pegol | Sham |
|---|---|---|
| Time to Persistent Vision Loss | 17.02 (2.8 to 23.0) | 13.93 (1.3 to 23.2) |
Collected over All-cause mortality (ACM): From randomization up to 24 months Serious Adverse events (SAEs) and non-SAEs: From first dose up to 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Avacincaptad Pegol Only (up to 12 Months) | 4/225 (1.8%) | 31/225 (13.8%) | 100/225 (44.4%) |
| Avacincaptad Pegol Only (12 to 24 Months) | 1/96 (1%) | 18/96 (18.8%) | 51/96 (53.1%) |
| Avacincaptad Pegol and Sham Only (12 to 24 Months) | 4/93 (4.3%) | 16/93 (17.2%) | 41/93 (44.1%) |
| Sham Only (up to 12 Months) | 1/222 (0.5%) | 36/222 (16.2%) | 83/222 (37.4%) |
| Sham Only (12 to 24 Months) | 7/203 (3.4%) | 25/203 (12.3%) | 77/203 (37.9%) |
| Event | Avacincaptad Pegol Only (up to 12 Months) | Avacincaptad Pegol Only (12 to 24 Months) | Avacincaptad Pegol and Sham Only (12 to 24 Months) | Sham Only (up to 12 Months) | Sham Only (12 to 24 Months) |
|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/225 | 0/96 | 2/93 | 0/222 | 0/203 |
| Cerebrovascular accidentNervous system disorders | 1/225 | 0/96 | 1/93 | 1/222 | 3/203 |
| Microcytic anaemiaBlood and lymphatic system disorders | 0/225 | 0/96 | 1/93 | 0/222 | 0/203 |
| Normocytic anaemiaBlood and lymphatic system disorders | 0/225 | 0/96 | 1/93 | 0/222 | 0/203 |
| Atrial tachycardiaCardiac disorders | 0/225 | 0/96 | 1/93 | 0/222 | 0/203 |
| Cardiac failure congestiveCardiac disorders | 1/225 | 0/96 | 1/93 | 1/222 | 0/203 |
| Barrett's oesophagusGastrointestinal disorders | 0/225 | 0/96 | 1/93 | 0/222 | 0/203 |
| Gastric haemorrhageGastrointestinal disorders | 0/225 | 0/96 | 1/93 | 0/222 | 0/203 |
| Biliary obstructionHepatobiliary disorders | 0/225 | 0/96 | 1/93 | 0/222 | 0/203 |
| Clostridium difficile infectionInfections and infestations | 1/225 | 0/96 | 1/93 | 0/222 | 0/203 |
| Event | Avacincaptad Pegol Only (up to 12 Months) | Avacincaptad Pegol Only (12 to 24 Months) | Avacincaptad Pegol and Sham Only (12 to 24 Months) | Sham Only (up to 12 Months) | Sham Only (12 to 24 Months) |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 7/225 | 11/96 | 14/93 | 7/222 | 26/203 |
| Conjunctival haemorrhageEye disorders | 31/225 | 14/96 | 9/93 | 18/222 | 5/203 |
| Choroidal neovascularisationEye disorders | 21/225 | 11/96 | 8/93 | 11/222 | 19/203 |
| Intraocular pressure increasedInvestigations | 22/225 | 9/96 | 5/93 | 4/222 | 1/203 |
| FallInjury, poisoning and procedural complications | 14/225 | 9/96 | 8/93 | 17/222 | 12/203 |
| Urinary tract infectionInfections and infestations | 14/225 | 3/96 | 2/93 | 13/222 | 18/203 |
| CataractEye disorders | 6/225 | 7/96 | 4/93 | 9/222 | 10/203 |
| Punctate keratitisEye disorders | 14/225 | 5/96 | 5/93 | 15/222 | 5/203 |
| NasopharyngitisInfections and infestations | 4/225 | 4/96 | 6/93 | 6/222 | 3/203 |
| Conjunctival hyperaemiaEye disorders | 12/225 | 1/96 | 1/93 | 13/222 | 5/203 |
Intent-to-treat (ITT) analysis set consisted of all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | Avacincaptad Pegol | Sham | Total |
|---|---|---|---|
| Mean | 76.3 ± 8.6 | 76.7 ± 8.8 | 76.5 ± 8.7 |
| Sex: Female, Male(Participants) | Avacincaptad Pegol | Sham | Total |
|---|---|---|---|
| Female | 154 | 156 | 310 |
| Male | 71 | 66 | 137 |
| Ethnicity (NIH/OMB)(Participants) | Avacincaptad Pegol | Sham | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 23 | 50 |
| Not Hispanic or Latino | 168 | 178 | 346 |
| Unknown or Not Reported | 30 | 21 | 51 |
| Race (NIH/OMB)(Participants) | Avacincaptad Pegol | Sham | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 182 | 186 | 368 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 41 | 34 | 75 |
Showing the first 100 of 205 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from Jun 2020 to primary completion in Jul 2022, 25 months.
Results were first posted in Dec 2023, 1 year 5 months after primary completion. A results delay was requested in Jul 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avacincaptad pegol